Ascentage Pharma Group International provided an update focusing on significant clinical data presentations from the ASH 2025 Annual Meeting concerning its pipeline assets, signed by CEO Dajun Yang on November 4, 2025. The company files annual reports on Form 20-F.
Key Pipeline Clinical Data Highlights:
Olverembatinib (HQP1351):
- Global Phase III POLARIS-1 Study (ND Ph+ ALL) demonstrated a 64.2% MRD-negative CR rate by the end of induction therapy.
- In TKI-Resistant Chronic Myeloid Leukemia in Chronic Phase (CML-CP), Olverembatinib significantly outperformed Best Available